Search -

Displaying 1 - 20 of 32

Sort: Relevancy | Date

Presentation TCT 2025

TCT 520: Revascularization in HBR Made Safer: Leveraging Sirolimus-DCB and SAPT

Presenter: Victor Alfonso Jimenez Diaz

October 28, 2025

Presentation TCT 2024

TCT 956: Validation of the VARC-HBR Criteria in TAVI Patients on Oral Anticoagulation

Presenter: Daniel Overduin

October 30, 2024

Presentation TCT 2024

TCT 242: Prospective Validation of the ARC-HBR, PRECISE-DAPT, and PARIS Risk Prediction Model in the All-Comer PIONEER IV Trial

Presenter: TsungYing Tsai

October 28, 2024

Presentation TCT 2024

From ARC-HBR and PRECISE-DAPT to PRECISE-2: Development and Validation of a Novel Universal Bleeding Risk Score

Presenter: Marco Valgimigli

October 27, 2024

Presentation TCT 2023

The Primary Endpoint Results from the COMPARE 60/80 HBR Trial: A Randomized Controlled Multi-Center Trial Comparing Ultrathin With Thin Strut Stents in High Bleeding Risk Patients With an Abbreviated DAPT Duration

Presenter: Pieter Smits

October 25, 2023

Presentation TCT 2022

Coronary DCB in HBR Patients: An Alternative to DES?

Presenter: Tuomas Rissanen

September 18, 2022

Presentation TCT 2022

Does It Matter What Stent I Use in a HBR Patient?

Presenter: Pieter Smits

September 18, 2022

Presentation TCT 2021

Latest Evidence on Short DAPT & HBR Patients

Presenter: Rafael Cavalcante

November 06, 2021

News Conference News TCT 2021

More DAPT Duration Data, More Calls to Tailor to Individual Patients

Shelley Wood

November 05, 2021

Presentation TCT 2021

Latest HBR Clinical Evidence

Presenter: Marco Valgimigli

November 04, 2021

Presentation TCT 2020

The XIENCE Short DAPT Program: XIENCE 90/28 - Evaluating the Safety of 3-month and 1-month DAPT in HBR Patients

Presenter: Roxana Mehran

October 15, 2020

Presentation TCT 2020

TCT 062: Short Term Dual Anti-Platelet Therapy Followed by P2Y12 Monotherapy After Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Control Trials

Presenter: Mohammad Saud Khan

October 14, 2020

Presentation TCT 2020

TCT 066: Ischemic and Bleeding Outcomes in Patients With vs. Without Atrial Fibrillation: Analysis From the Onyx ONE Month DAPT Program

Presenter: Sanjeevan Pasupati

October 14, 2020

Presentation TCT 2020

TCT 056: Prolonged Dual Antiplatelet Therapy in Patients With or Without Prior Myocardial Infarction: An Updated Systematic Review and Meta-Analysis

Presenter: Mauro Chiarito

October 14, 2020

Presentation TCT 2020

TCT 065: Cangrelor Use Patterns and Transition to Oral P2Y12 Inhibitors Among Patients With Myocardial Infarction: Early Results From the Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes (CAMEO) Registry

Presenter: Jennifer Rymer

October 14, 2020

Presentation TCT 2020

TCT 060: Contribution of ESC DAPT Guideline-Endorsed High Thrombotic Risk Features to Long-Term Clinical Outcomes Among Patients With and Without High Bleeding Risk After PCI

Presenter: Hao-Yu Wang

October 14, 2020

Presentation TCT 2020

TCT 057: Clinical Outcomes According to Lesion Complexity in High Bleeding Risk Patients Treated With 1-Month Dual Antiplatelet Therapy Following PCI: Analysis From the Onyx ONE Clear Study

Presenter: David Kandzari

October 14, 2020

Presentation TCT 2020

TCT 055: Short Duration of Dual Antiplatelet Therapy After PCI With DES: An Updated Meta-Analysis of Randomized Controlled Trials.

Presenter: Ahmed Elzanaty

October 14, 2020

Presentation TCT 2020

TCT 067: Antithrombotic Treatment Strategies in Patients Older than 75 Years With Atrial Fibrillation After Percutaneous Coronary Intervention With Drug-Eluting Stents. The PACO-PCI Registry

Presenter: Jose de la Torre Hernandez

October 14, 2020

Presentation TCT 2020

TCT 059: Meta-Analysis of Bleeding, MACE and Mortality in Clinical Trials of Time-Constrained Dual-Antiplatelet Therapy After PCI

Presenter: Jennifer Ramsay

October 14, 2020

Advertisement

TCT 520: Revascularization in HBR Made Safer: Leveraging Sirolimus-DCB and SAPT

TCT 956: Validation of the VARC-HBR Criteria in TAVI Patients on Oral Anticoagulation

TCT 242: Prospective Validation of the ARC-HBR, PRECISE-DAPT, and PARIS Risk Prediction Model in the All-Comer PIONEER IV Trial

From ARC-HBR and PRECISE-DAPT to PRECISE-2: Development and Validation of a Novel Universal Bleeding Risk Score

The Primary Endpoint Results from the COMPARE 60/80 HBR Trial: A Randomized Controlled Multi-Center Trial Comparing Ultrathin With Thin Strut Stents in High Bleeding Risk Patients With an Abbreviated DAPT Duration

Coronary DCB in HBR Patients: An Alternative to DES?

Does It Matter What Stent I Use in a HBR Patient?

Latest Evidence on Short DAPT & HBR Patients

More DAPT Duration Data, More Calls to Tailor to Individual Patients

Latest HBR Clinical Evidence

The XIENCE Short DAPT Program: XIENCE 90/28 - Evaluating the Safety of 3-month and 1-month DAPT in HBR Patients

TCT 062: Short Term Dual Anti-Platelet Therapy Followed by P2Y12 Monotherapy After Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Control Trials

TCT 066: Ischemic and Bleeding Outcomes in Patients With vs. Without Atrial Fibrillation: Analysis From the Onyx ONE Month DAPT Program

TCT 056: Prolonged Dual Antiplatelet Therapy in Patients With or Without Prior Myocardial Infarction: An Updated Systematic Review and Meta-Analysis

TCT 065: Cangrelor Use Patterns and Transition to Oral P2Y12 Inhibitors Among Patients With Myocardial Infarction: Early Results From the Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes (CAMEO) Registry

TCT 060: Contribution of ESC DAPT Guideline-Endorsed High Thrombotic Risk Features to Long-Term Clinical Outcomes Among Patients With and Without High Bleeding Risk After PCI

TCT 057: Clinical Outcomes According to Lesion Complexity in High Bleeding Risk Patients Treated With 1-Month Dual Antiplatelet Therapy Following PCI: Analysis From the Onyx ONE Clear Study

TCT 055: Short Duration of Dual Antiplatelet Therapy After PCI With DES: An Updated Meta-Analysis of Randomized Controlled Trials.

TCT 067: Antithrombotic Treatment Strategies in Patients Older than 75 Years With Atrial Fibrillation After Percutaneous Coronary Intervention With Drug-Eluting Stents. The PACO-PCI Registry

TCT 059: Meta-Analysis of Bleeding, MACE and Mortality in Clinical Trials of Time-Constrained Dual-Antiplatelet Therapy After PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content